|Titre :||Prevalence of New Psychoactive Substances (NPS) and conventional drugs of abuse (DOA) in high risk populations from Paris (France) and its suburbs: A cross sectional study by hair testing (2012-2017) (2019)|
|Auteurs :||I. A. LARABI ; N. FABRESSE ; I. ETTING ; L. NADOUR ; G. PFAU ; J. H. RAPHALEN ; P. PHILIPPE ; Y. EDEL ; J. C. ALVAREZ|
|Type de document :||Article : Périodique|
|Dans :||Drug and Alcohol Dependence (Vol.204, November 2019)|
|Article en page(s) :||art. 107508|
|Discipline :||PRO (Produits, mode d'action, méthode de dépistage / Substances, action mode, screening methods)|
Thésaurus géographiqueFRANCE ; ILE-DE-FRANCE
Thésaurus mots-clésDROGUES DE SYNTHESE ; PRODUIT ILLICITE ; POPULATION A RISQUE ; PREVALENCE ; ANALYSE CHIMIQUE ; PHANERES ; DEPISTAGE ; DEPENDANCE ; INTOXICATION ; ETUDE TRANSVERSALE ; HOPITAL
BACKGROUND: The aim of the present study is to describe the prevalence of NPS and conventional DOA in Paris and its suburbs over a six-year period using hair testing approach.
METHOD: Hair was sampled in patients admitted to different departments of Paris hospitals between 2012 and 2017. Two high-risk populations were mainly considered: 1) drug-dependent and 2) acutely intoxicated patients. Segmental hair analysis was performed by validated LC-MS/MS method to screen for DOA and 83 NPS.
RESULTS: 480 patients (280M/200F, 15-70 years) were included. 141 patients tested positive for NPS (99M/42F; median age: 33). NPS prevalence was 29%, that of amphetamines, cocaine and opioids were 32%, 38.5% and 52%, respectively. 27 NPS were identified, 4-MEC and mephedrone (number of cases n=24 each) were the most detected cathinones. JWH-122 (n=1) was the only detected synthetic cannabinoid while ketamine (n=104) was present in numerous NPS users (67%). 3-fluorofentanyl (n=1), furanylfentanyl (n=1), N-ethylpentylone (n=2), pentedrone (n=2), mexedrone (n=1), methcathinone (n=3), 6-APDB (n=2), TFMPP (n=2), 2-CE (n=1), 3,4-MD-alphaPHP (n=1) and dextromethorphan (n=27) were identified for the first time in hair. Users were found to have more than one NPS in 53% of cases, mostly in combination with conventional DOA. The number of detected NPS rose from 5 in 2012 to 42 in 2017. A broad range of hair concentrations (0.001-318ng/mg) was found, but the low median concentrations seem to show an occasional exposure more than chronic use.
CONCLUSION: NPS screening should be assessed in routine clinical practice, especially in high-risk populations.
Prevalence of NPS in Paris in its suburb from 2012 to 2017 using hair analysis.
NPS prevalence as high as conventional DOA.
Screening of NPS should be performed in routine clinical practice in high-risk population.
|Domaine :||Drogues illicites / Illicit drugs|
|Affiliation :||Department of Pharmacology and Toxicology, Versailles Saint-Quentin-en-Yvelines University, Inserm U-1173, Raymond Poincare Hospital, AP-HP, Garches, France|